Content area
Full text
Sapien Biosciences, an Apollo subsidiary, to spearhead the introduction of cutting-edge genomic testing across the Apollo network, as part of its personalised medicine initiatives
Apollo Hospitals announced the introduction of several genomic tests as part of its personalised medicine initiative. The introduction of these tests, over the next few months, shall be spearheaded by the Apollo Hospitals subsidiary, Sapien Biosciences.
Previously Apollo, through Sapien, had launched a personalised test that combines assessment of a patients' genotype and their platelet function to allow the physician to personalise anti-platelet therapy.
Sapien has been working with multiple genetic testing providers in India over the last few months to develop and customise these tests for introduction at Apollo. The first of these tests, to be launched shortly, shall be a clinical genomics panel for oncology that is designed to identify the mutations that drive cancer initiation and progression. Insights obtained from this test will reportedly enable prediction of patients' response to their medication allowing the physician to tailor treatment to the patients' genomic profile.
Along with the cancer genomic panels, Apollo will also be launching other panels that will...